AG
BHVN

Aperio Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Aperio Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$266K Buy
+3,109
New +$263K ﹤0.01% 2228
2019
Q3 		– Sell
-1,617
Closed -$71K – 3079
2019
Q2 		$71K Buy
+1,617
New +$91.2K ﹤0.01% 2475

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's BHVN Position: Q4 2020 in Review

Aperio Group opened a new position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2020: 3,109 shares worth $266K. The stake represents ﹤0.01% of the portfolio and ranks #2228 among its holdings. This is a return to the name: Aperio Group previously reported a position in BHVN as recently as Q2 2019.

Aperio Group first reported a position in BHVN in Q2 2019 and has held it in 2 quarters since. 238 funds tracked by Wall St. Rank hold BHVN as of Q4 2020.

  • Aperio Group held 3,109 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $266K as of Q4 2020.
  • Biohaven Pharmaceutical Holding Company Ltd. was a new Aperio Group position in Q4 2020.
  • Biohaven Pharmaceutical Holding Company Ltd. made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2228 holding.
  • Aperio Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and has held it in 2 quarters since.
  • 238 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.